TOT Biopharm opens new production facility in China
TOT Biopharm has held an inauguration ceremony for its new factory complex in Suzhou, China.
TOT Biopharm Company Ltd has opened a new factory in eastern China.
Stage one of its new high-tech production factory complex in the Suzhou Industrial Park has now been completed, with an inauguration ceremony being held in November.
The $100 million factory will specialise in the research and development, production and marketing of anti-cancer drugs and represents a milestone in the cooperation between the biopharmaceutical sectors in mainland China and Taiwan.
As such, the inauguration ceremony was attended by business leaders from both regions, including Wang Shaobang, deputy director of the Taiwan Affairs Office of Jiangsu Province; Yang Zhiping, director of Suzhou Industrial Park; and Gao Konglian, deputy chairman of Straits Exchange Foundation.
The first stage of the new factory complex provides manufacturing facilities for an oral anti-cancer drug, alongside production facilities for cytotoxics, non-cytotoxics and an injected anti-cancer drug, and a GMP bio pilot plant.
TOT Biopharm will now commence construction on the second stage of its new factory complex, providing additional production capacity.
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...